vTv Therapeutics, Inc. - VTVT Total Company Value-to-Revenue Ratio

Official company branding of vTv Therapeutics Inc. (VTVT)

vTv Therapeutics Inc. (VTVT) develops small molecules for the treatment of type 1 diabetes, leveraging FDA priority status. Patents for these small-molecule agents create a significant barrier to entry for new players. A business valuation via EV/Sales captures the company's real value excluding debt, and this metric currently stands at -429.70. High costs associated with Phase 3 trials further restrict access to this niche.

VTVT vTv Therapeutics: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/21/2026

Financial and market metric breakdowns for vTv Therapeutics Inc (VTVT)

Fundamental valuation:vTv Therapeutics Inc. - VTVT
Flagship merchandise of vTv Therapeutics, Inc.

For vTv Therapeutics Inc. (VTVT), whose model is based on clinical trials without proprietary manufacturing plants and strict compliance with environmental regulations, this metric determines the market value of the business minus net debt relative to sales volume. By analyzing the current enterprise value-to-revenue ratio, an investor can assess the premium paid for intellectual capital and the sustainability of the company's valuation in the absence of a large-scale production cycle.

Direct competitors

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BioAge Labs Inc. (BIOA) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume BMEA (Biomea Fusion, Inc.)|QNCX (quincetx.com) - EV/Sales Multiple|GUTS: Business Value to Revenue|Company Value to Revenue ATPC (Agape ATP Corp)|Total Company Value-to-Revenue Ratio Pluristem Therapeutics|Enterprise Value-to-Revenue Ratio synlogictx.com SYBX|LPCN: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)